Andrea Newkirk, an analyst from Goldman Sachs, has initiated a new Buy rating on Revolution Medicines (RVMD).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrea Newkirk has given her Buy rating due to a combination of factors related to Revolution Medicines’ strategic focus and promising clinical developments. The company is at the forefront of precision oncology, concentrating on a portfolio of RAS(On) inhibitors aimed at treating RAS-addicted cancers such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Revolution Medicines’ lead asset, daraxonrasib, is undergoing advanced clinical trials, including two Phase 3 registrational trials for metastatic PDAC and NSCLC. The potential for daraxonrasib to be used in combination with other therapies offers a promising avenue for deeper and more durable responses, which could significantly enhance its commercial success. These factors, combined with the projected peak global sales of $12.1 billion for daraxonrasib, underpin the Buy rating and highlight the underappreciated commercial opportunities for the company.
In another report released on July 9, Bank of America Securities also maintained a Buy rating on the stock with a $78.00 price target.